© 1994 British Society for Rheumatology
research-article |
SERUM CYTOKINES (IL-6, TNF-
, IL-1ß AND IFN-
) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWEEN SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITY
*Department of Rheumatology Barcelona, Spain
Department of Biochemistry, Hospital Clinic Barcelona, Spain
Provincial, University of Barcelona Barcelona, Spain
The aim of our study was to analyse the serum interleukin-6 (IL-6), tumour necrosis factor-
(TNF-), interleukin-1ß (IL-1ß) and interferon-
(IFN-) levels in patients with AS and their relationship with disease activity. An ELISA test was used to analyse serum cytokine (IL-6, TNF-, IL-1ß and IFN-) levels in 69 patients with AS. Results were compared with those from 43 patients with RA and 36 patients with non-inflammatory back pain. The relationship between serum concentrations of the different cytokines and parameters of disease activity and severity in AS patients was also evaluated. IL-6 and TNF- serum levels, but not IL-1ß and IFN-, were significantly higher in AS than in NIBP. However, patients with RA showed higher serum levels of IL-6, TNF- and IFN- than both AS and NIBP patients. In AS, IL-6 correlated with clinical parameters of disease activity with significant correlation being observed with laboratory parameters of inflammation such as ESR, CRP, platelet count and clinical parameters of severity such as vertebral mobility. TNF- did not correlate with laboratory or clinical parameters of activity. Macrophagic cytokines (TNF- and IL-6), are increased in AS patients and IL-6 closely correlated with the activity of the disease.
KEY WORDS: Interleukin, Spondyloarthropathy, Sera
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I C van Eijk, M J L Peters, E H Serne, I E van der Horst-Bruinsma, B A C Dijkmans, Y M Smulders, and M T Nurmohamed Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor {alpha} blockade Ann Rheum Dis, March 1, 2009; 68(3): 362 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Choi, J. H. Kim, E.-J. Kang, S.-W. Lee, M.-C. Park, Y.-B. Park, and S.-K. Lee Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis Rheumatology, December 1, 2008; 47(12): 1775 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Visvanathan, C Wagner, J C Marini, D Baker, T Gathany, J Han, D van der Heijde, and J Braun Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab Ann Rheum Dis, April 1, 2008; 67(4): 511 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G.-J. Ooi, G. Galatowicz, V. L. Calder, and S. L. Lightman Cytokines and Chemokines in Uveitis - Is there a Correlation with Clinical Phenotype? Clin. Med. Res., December 1, 2006; 4(4): 294 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marcora, F. Casanova, E. Williams, J. Jones, R. Elamanchi, and A. Lemmey Preliminary evidence for cachexia in patients with well-established ankylosing spondylitis Rheumatology, November 1, 2006; 45(11): 1385 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R J Francois, L Neure, J Sieper, and J Braun Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor {alpha} in two patients with early disease and transforming growth factor {beta} in three more advanced cases Ann Rheum Dis, June 1, 2006; 65(6): 713 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Collantes-Estevez, M. C. Munoz-Villanueva, P. Zarco, J. C. Torre-Alonso, J. Gratacos, C. Gonzalez, R. Sanmarti, J. D. Canete, and (Spanish Spondyloarthropathies Study Group) Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study Rheumatology, December 1, 2005; 44(12): 1555 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mpofu, F. Fatima, and R. J. Moots Anti-TNF-{alpha} therapies: they are all the same (aren't they?) Rheumatology, March 1, 2005; 44(3): 271 - 273. [Full Text] [PDF]
|
|
|
|
|
|
S. Paul and A. Keat Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor {alpha} blockade Rheumatology, January 1, 2005; 44(1): 17 - 23. [Full Text] [PDF]
|
|
|
|
|
|
A Calin, B A C Dijkmans, P Emery, M Hakala, J Kalden, M Leirisalo-Repo, E M Mola, C Salvarani, R Sanmarti, J Sany, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis Ann Rheum Dis, December 1, 2004; 63(12): 1594 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Imrich, J Rovensky, M Zlnay, Z Radikova, L Macho, M Vigas, and J Koska Hypothalamic-pituitary-adrenal axis function in ankylosing spondylitis Ann Rheum Dis, June 1, 2004; 63(6): 671 - 674. [Abstract] [Full Text]
|
|
|
|
|
|
C Keller, A Webb, and J Davis Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review Ann Rheum Dis, December 1, 2003; 62(12): 1128 - 1132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Burgos-Vargas Juvenile onset spondyloarthropathies: therapeutic aspects Arch. Dis. Child., April 1, 2003; 88(4): 312 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J A G van Roon and J W J Bijlsma Th2 mediated regulation in RA and the spondyloarthropathies Ann Rheum Dis, November 1, 2002; 61(11): 951 - 954. [Full Text] [PDF]
|
|
|
|
|
|
R Burgos-Vargas Juvenile onset spondyloarthropathies: therapeutic aspects Ann Rheum Dis, November 1, 2002; 61(90003): iii33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Braun, J Sieper, M Breban, E Collantes-Estevez, J Davis, R Inman, H Marzo-Ortega, and H Mielants Anti-tumour necrosis factor {alpha} therapy for ankylosing spondylitis: international experience Ann Rheum Dis, November 1, 2002; 61(90003): iii51 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Gorman, K. E. Sack, and J. C. Davis Jr. Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor {alpha} N. Engl. J. Med., May 2, 2002; 346(18): 1349 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Toussirot, F. Michel, and D. Wendling Bone density, ultrasound measurements and body composition in early ankylosing spondylitis Rheumatology, August 1, 2001; 40(8): 882 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-J. Ho, P.-Q. Chen, C.-Y. Chang, and F.-J. Lu The oxidative metabolism of circulating phagocytes in ankylosing spondylitis: determination by whole blood chemiluminescence Ann Rheum Dis, May 1, 2000; 59(5): 338 - 341. [Abstract] [Full Text]
|
|
|
|
|
|
J. D Cañete, S. E Martínez, J. Farrés, R. Sanmartí, M. Blay, A. Gómez, G. Salvador, and J. Muñoz-Gómez Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies Ann Rheum Dis, April 1, 2000; 59(4): 263 - 268. [Abstract] [Full Text]
|
|